Naveen Pemmaraju
A5088307376- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Cutaneous lymphoproliferative disorders research
- Multiple Myeloma Research and Treatments
- Histone Deacetylase Inhibitors Research
- Eosinophilic Disorders and Syndromes
- Protein Degradation and Inhibitors
- Lymphoma Diagnosis and Treatment
- Toxin Mechanisms and Immunotoxins
- Neutropenia and Cancer Infections
- Fungal Infections and Studies
- Kruppel-like factors research
- Hemoglobinopathies and Related Disorders
- Hematopoietic Stem Cell Transplantation
- Cancer Genomics and Diagnostics
- Retinoids in leukemia and cellular processes
- Epigenetics and DNA Methylation
- Pneumocystis jirovecii pneumonia detection and treatment
- Immunotherapy and Immune Responses
- Hematological disorders and diagnostics
- Childhood Cancer Survivors' Quality of Life
The University of Texas MD Anderson Cancer Center
2016-2025
Moffitt Cancer Center
2024
Cornell University
2024
The University of Kansas Cancer Center
2024
Trillium Therapeutics (Canada)
2022
Astellas Pharma (China)
2022
Bristol-Myers Squibb (Japan)
2022
Bristol-Myers Squibb (Germany)
2022
Novartis (Switzerland)
2022
AbbVie (United States)
2022
Abstract Preclinical models have shown that blocking PD-1/PD-L1 pathways enhances antileukemic responses. Azacitidine upregulates PD-1 and IFNγ signaling. We therefore conducted this single-arm trial, in which patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) were treated azacitidine 75 mg/m2 days 1 to 7 intravenously or subcutaneously nivolumab 3 mg/kg on 14, every 4 6 weeks. For the seventy who treated, median age was 70 years (range, 22–90) number of prior therapies...
Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations indicated potential synergistic interaction their combination.
Venetoclax (VEN), a selective BCL2 inhibitor, has single-agent activity in relapsed and refractory (R/R) acute myeloid leukemia (AML), efficacy lower intensity combinations for treatment-naïve elderly AML patients. VEN treatment R/R have not been previously reported.All patients (including AML, myelodysplastic syndrome (MDS), blastic plasmacytoid dendritic cell neoplasm (BPDCN)) treated with the salvage setting were reviewed.Forty-three median age 68 (range, 25-83) (91%), MDS (5%), or BPDCN...
Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive hematologic cancer that caused by transformed dendritic cells overexpress interleukin-3 receptor subunit alpha (IL3RA or CD123). Tagraxofusp (SL-401) a CD123-directed cytotoxin consisting of human fused to truncated diphtheria toxin.In this open-label, multicohort study, we assigned 47 patients with untreated relapsed BPDCN receive intravenous infusion tagraxofusp at dose 7 μg 12 per kilogram body weight on days 1 5 each...
Sixty percent of newly diagnosed patients with acute myeloid leukemia (ND-AML) receiving frontline therapy attain a complete response (CR), yet 30%-40% relapse. Relapsed or refractory AML (R/R-AML) remains particularly adverse population necessitating improved therapeutic options. This phase Ib/II study evaluated the safety and efficacy fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin combined B-cell lymphoma-2 inhibitor venetoclax in ND-AML R/R-AML.The IB portion...
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with dismal outcomes for which no standard therapy exists. We found that primary BPDCN cells were dependent on the antiapoptotic protein BCL2 and uniformly sensitive to inhibitor venetoclax, as measured by direct cytotoxicity, apoptosis assays, dynamic BH3 profiling. Animals bearing patient-derived xenografts had disease responses improved survival after venetoclax treatment in vivo Finally, we...
BACKGROUND The clinical efficacy of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD) plus ponatinib has not been compared with that HCVAD dasatinib in patients Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL) a randomized trial. METHODS authors analyzed 110 newly diagnosed Ph+ ALL who were enrolled 2 consecutive, prospective, phase trials frontline either (63 patients) or (47 patients). Propensity score analysis 1:1 matching the...
Purpose The aim of the current study was to determine whether degree mutation clearance at remission predicts risk relapse in patients with acute myeloid leukemia (AML). Patients and Methods One hundred thirty-one previously untreated AML who received intensive induction chemotherapy attained morphologic complete (CR) day 30 were studied. Pretreatment CR bone marrow analyzed using targeted capture DNA sequencing. We association between (MC) on basis variant allele frequency (VAF) (MC2.5: if...
Targeting the BCL-X
The combination of venetoclax and 5-azacitidine (5-AZA) for older or unfit patients with acute myeloid leukemia (AML) improves remission rates survival compared 5-AZA alone. We hypothesized that the addition to cladribine (CLAD)/low-dose araC (low-dose cytarabine [LDAC]) alternating backbone may further improve outcomes newly diagnosed AML.This is a phase II study investigating CLAD/LDAC in (≥ 60 years) AML. primary objective was composite complete response (CR) rate (CR plus CR incomplete...
Abstract The combination of ponatinib, a third‐generation BCR::ABL1 tyrosine kinase inhibitor, with hyper‐CVAD chemotherapy resulted in high rates complete molecular remissions and survival, without the need for stem cell transplantation (SCT) most patients Philadelphia chromosome(Ph)‐positive acute lymphocytic leukemia (ALL). Confirming these results large cohort longer follow‐up would establish this regimen as new standard care. Adults newly diagnosed Ph‐positive ALL were treated regimen....
Polycythemia vera is a chronic myeloproliferative neoplasm characterized by erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory hormone hepcidin, restricts availability for erythropoiesis. The safety and efficacy rusfertide in patients with phlebotomy-dependent polycythemia are unknown.